Medica Instruments, a division of Mahape Pharma, manufactures some of the most popular pain medications on the market, including Dilaudid, which is used to treat severe pain.

But Medica’s owners and representatives say the company’s chief executive officer, David L. Loomis, is refusing to prescribe Medica instruments because of concerns that some of its products may contain dangerous contaminants.

The FDA requires Medica to report the presence of potentially harmful chemicals on its product labels, but it has so far failed to do so.

Medica says the problem is with the medica’s manufacturing process and its handling of toxic ingredients.

Medication makers are also worried that the FDA may revoke its licenses for certain products in the future.

Loomis told the Journal that the problem arose after Medica acquired an additive for its drugs, which the company has not yet disclosed.

The additive was manufactured by an Australian company called Medica, but Medica is owned by a subsidiary of the Indian company Mahape, and it has a license to manufacture the additive, according to the Journal.

Media, which was founded in 1999, has been involved in the pharmaceutical industry since its inception.

Medica has long been known for its products, which are sold as a generic and brand name.

In 2016, Medica sold Medica brand drugs to Medicare for about $1.7 billion.

That was the largest single acquisition by a drug maker since 2002, according the Journal, and more than double the amount Medica paid for the company in 2015.

In 2015, Medias CEO, Paul L. H. Zampini, resigned amid a scandal involving mismanagement of company funds, a complaint that the company settled with the Department of Justice.

Zampsini, who also serves as president of the American Academy of Pain Medicine, was accused of mismanaging Medica funds by failing to properly account for a $3.8 million bonus he received from the company, according an article by the Journal last year.

Media has been selling its pain meds for years.

Its first pain drug, Dilaudido, was approved in 2010, and its first cancer drug, Imetrex, was introduced in 2013.